drugset / Trial / NCT01105130
L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors
Phase 2
Completed
140 enrolled
Wake Forest University Health Sciences
National Cancer Institute (NCI) · collab
RandomizedParallel-groupQuadruple-blindSupportive care
Summary
RATIONALE: L-arginine supplements may improve the quality of life and erectile function in men who are prostate cancer survivors. PURPOSE: This randomized phase II trial is studying how well L-arginine supplementation works with or without enzyme inhibitors in treating erectile function and quality of life of prostate cancer survivors previously treated with radiation therapy.
Timeline
- Start
- 2010-10-01
- Primary completion
- 2014-02-04
- Completion
- 2014-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-arginine | Small molecule | — | Oral |